1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Guhan Pharmaceutical Group Co., Ltd. Class A

Guhan Pharmaceutical Group Co., Ltd. Class A

SSZSE:000590
8.39
CNY
+0.06
(+0.72%)
-0.21EPS
1.96BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.15
0.91
1.32
1.42
1.48
0.78
1.32
1.15
1.26
1.46
1.69
1.43
1.41
1.35
Basic EPS, GAAP
-0.74
-0.38
0.1
0.25
0.08
-0.16
0.18
0.09
0.15
0.08
0.11
-0.52
-0.21
-0.22
Free Cash Flow per Basic Share
-0.05
-0.62
-0.41
-0.22
-0.48
-0.09
-0.03
0.07
- -
0.15
-0.21
-0.06
-0.08
- -
Dividend per Share
0.2
0.02
0.01
- -
- -
0.01
0.01
- -
- -
- -
0.02
0.01
0.01
0.01
Book Value per Share
1.21
0.82
0.92
1.17
2.44
2.42
2.6
2.69
2.84
2.92
3.02
2.5
2.29
2.22
Tangible Book Value per Share
0.55
0.13
0.07
0.37
1.73
1.85
2.04
2.12
2.28
1.69
1.92
1.9
1.77
1.72
Basic Weighted Avg Shares
223
223
223
223
233
240
240
239
239
240
240
239
239
239
Sales/Revenue/Turnover
256
203
295
317
344
186
315
275
301
351
405
343
338
324
Operating Margin (%)
-23.98
-29.36
12.1
7.81
4.82
-19.25
8.81
8.14
11.34
4.62
5.06
-5.71
-5.56
-6.16
Depreciation Expense
17
13
14
15
14
16
14
14
19
24
28
29
32
- -
Net Income, GAAP
-164
-86
22
55
19
-38
42
23
35
18
25
-125
-51
-52
Effective Tax Rate (%)
- -
- -
27.53
24.36
55.12
- -
20.59
17.8
15.29
17.09
16.14
- -
- -
- -
Profit Margin (%)
-64.24
-42.23
7.59
17.38
5.58
-20.55
13.47
8.26
11.78
5.17
6.24
-36.56
-14.96
-15.91
Working Capital
36
-63
-26
30
358
346
338
348
367
258
291
264
178
171
LT Debt
- -
- -
- -
- -
20
20
- -
9
6
95
83
84
51
59
Total Equity
270
184
206
264
583
580
622
645
682
702
728
601
549
534
Return on Invested Capital (%)
- -
- -
12.75
22.56
2.55
- -
7.74
4.1
6.09
2.69
2.17
- -
- -
- -
Return on Capital (%)
- -
- -
9.55
20.37
6.07
- -
7.06
3.55
5.31
2.49
3.54
- -
- -
- -
Return on Common Equity (%)
-43.97
-37.82
11.48
23.64
4.54
-6.57
7.06
3.59
5.35
2.63
3.55
-18.98
-8.82
-9.25

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
21
21
11
LT Borrowings
50
50
58
LT Finance Leases
1
1
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
239
239
239
Market Capitalization
2,684
2,797
1,956

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
379
366
358
Cash, Cash Equivalents & STI
178
147
141
Accounts Receivable, Net
2
2
2
Inventories
110
- -
122
Total Current Liabilities
201
195
187
Payables & Accruals
- -
- -
- -
ST Debt
21
21
11
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.6%
-2.72%
-8.61%
Free Cash Flow
-618.81%
-1,150.56%
34.9%
Net Income, GAAP
-108.56%
-122.05%
-59.74%
Sales/Revenue/Turnover
5.14%
4.91%
-1.61%
Total Cash Common Dividend
140.76%
300.61%
-3.25%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
77
70
70
127
343
2025
65
77
- -
113
338
2026
72
63
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.03
-0.06
-0.02
-0.41
-0.52
2025
-0.07
- -
- -
-0.15
-0.21
2026
-0.03
-0.03
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.01
2025
- -
- -
- -
- -
0.01
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Xue Feng
Full Time Employees
1,064
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Headquarters Office Building Hengyang HU China 421001
IPO Date
Jan 19, 1996
Website
tuspharma.cn
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Tus-Pharmaceutical Group Co., Ltd. operates primarily in the pharmaceutical sector, engaging in the development, production, and distribution of diverse medicinal and health products. The company offers an extensive portfolio, encompassing traditional Chinese medicines, Western pharmaceutical preparations, and health foods. Its product lines include nutritional supplements, remedies for cardiovascular and cerebrovascular conditions, children's nutrition, and treatments for colds and detoxification, alongside various injections. Recognized as a national high-tech enterprise, it stands as a significant entity within the proprietary Chinese medicine industry and is considered a leading integrated pharmaceutical company in Hunan, blending Chinese medicine, Western medicine, and biochemical products. The firm was established in 1956 and maintains its operational headquarters in Hengyang, China, having previously been known as Tus-Guhan Group Corp., Ltd.. Recent strategic moves include changes in ownership structure and various acquisitions and funding initiatives.